Related Experiment Videos
IPD-1151T: a prototype drug for IgE antibody synthesis modulation
A Koda1, Y Yanagihara, N Matsuura
1Department of Pharmacology, Gifu Pharmaceutical University, Japan.
Agents and Actions. Supplements
|January 1, 1991
Summary
IPD-1151T effectively inhibits immunoglobulin E (IgE) antibody formation in mice and allergic patients. This compound reduces specific IgE antibody titers and decreases interleukin-4 production, suggesting a novel therapeutic mechanism for allergic diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- Immunoglobulin E (IgE) plays a central role in allergic reactions.
- Inhibiting IgE formation is a key therapeutic strategy for allergic diseases.
Purpose of the Study:
- To investigate the inhibitory effect of IPD-1151T on IgE antibody formation.
- To elucidate the mechanism of action of IPD-1151T in suppressing IgE production.
Main Methods:
- Dose-dependent inhibition of IgE formation in BALB/c mice immunized with dinitrophenylated ascaris extract (DNP.As).
- Assessment of total and specific IgE levels in atopic patients treated with IPD-1151T.
- Evaluation of B cell Fc epsilon RII expression and interleukin-4 (IL-4) production from T-cell lines.
Main Results:
- IPD-1151T dose-dependently inhibited IgE antibody formation in mice without affecting IgM or IgG.
- Total and specific IgE levels decreased in atopic patients treated with IPD-1151T.
- Reduced Fc epsilon RII expression on B cells and decreased IL-4 production were observed.
Conclusions:
- IPD-1151T demonstrates significant inhibitory effects on IgE antibody formation.
- The compound's mechanism involves reducing IL-4 production and affecting B cell Fc epsilon RII expression.
- IPD-1151T shows potential as a therapeutic agent for IgE-mediated allergic diseases.